The data indicate that PD1-Fc-OX40L is able to bind PD-L1 and OX40 simultaneously, stimulate OX40 signaling in the absence of cross-linking, and provide improved control of tumor immunity as compared to combinations of PD1 and OX40 targeted antibodies. Here, TNFRSF4 is linked to neoplasm.